A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on in-Vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis.

Trial Profile

A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on in-Vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Atherosclerosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 24 May 2012 EudraCT reports actual initiation date is (1 Apr 2009) and trial status is recruiting.
    • 25 Dec 2009 Actual patient number (102) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top